Xiangcai Co

Xiangcai Co Stock-Based Compensation

The Stock-Based Compensation (SBC) of Xiangcai Co (600095.SS) as of Oct 23, 2026 is 12.46 M CNY. In the previous year, Stock-Based Compensation (SBC) was 9.54 M CNY — a change of 30.64% (higher).

Stock-Based Compensation

12.46 MCNY

YoY

30.64%

Last updated:

Stock-Based Compensation (SBC) of Xiangcai Co is 2022 12.46 M CNY. Stock-Based Compensation (SBC) of Xiangcai Co was 2021 9.54 M CNY. It decreases by 30.64% higher compared to the previous year.

The Xiangcai Co Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2021
9.54 M CNY
Jan 1, 2022
12.46 M CNY
The Xiangcai Co Stock-Based Compensation history
YEARStock-Based CompensationYoY
12.46 MCNY+30.64%
9.54 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Xiangcai Co Stock analysis

What does Xiangcai Co do? Xiangcai Co., Ltd. generates revenue through multiple business segments including non-GMO soybean products processing, pharmaceuticals, waterproof membrane manufacturing, and industrial plants. The company produces soybean protein isolate, soybean tissue protein, and soybean nutritious food under its soybean deep processing division. Its pharmaceutical segment focuses on thymopeptide enteric-coated tablets and other immune system treatment drugs. The waterproof membrane business manufactures and sells polyethylene polypropylene fiber coils, load-bearing coils, and joint profiles. Real estate development and property management contribute to the company's revenue through residential and industrial real estate projects. The primary buyers for soybean deep processing products include food manufacturers and health supplement companies seeking non-GMO ingredients. Pharmaceutical customers consist of hospitals, pharmacies, and healthcare providers purchasing thymopeptide enteric-coated tablets for immune system treatments. Waterproof membrane products are sold to construction companies and building contractors for infrastructure and residential projects. Real estate clients are residential buyers and industrial tenants requiring property development and management services. Xiangcai Co., Ltd. serves distinct market segments: food and beverage manufacturers for soybean products, healthcare institutions for pharmaceuticals, construction firms for waterproofing solutions, and residential/industrial property occupants for real estate services. The company's product portfolio spans from raw material processing to end-user applications across these sectors, creating diversified revenue streams. Xiangcai Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Xiangcai Co stock

Stock-Based Compensation (SBC) of Xiangcai Co is 12.46 M CNY in 2022.

Stock-Based Compensation (SBC) of Xiangcai Co changed from 9.54 M CNY to 12.46 M CNY, representing a 30.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Xiangcai Co since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Xiangcai Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Xiangcai Co

All Key Metrics — Xiangcai Co